-
公开(公告)号：US20240342128A1
公开(公告)日：2024-10-17
申请号：US18751933
申请日：2024-06-24
IPC分类号： A61K31/282 , A61K9/00 , A61K31/575 , A61K33/243 , A61P35/04 , C07F15/00 , C07H23/00 , C07J41/00 , C07J51/00
CPC分类号： A61K31/282 , A61K9/0019 , A61K31/575 , A61K33/243 , A61P35/04 , C07F15/0006 , C07H23/00 , C07J41/00 , C07J41/0055 , C07J51/00
摘要： The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula I and/or Formula II, preferably Compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducing an immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.
-
![SALTS AND CRYSTALLINE FORMS OF (3E) 3-[O-[(PHOSPHONOOXY)METHYL]OXIME]-PREGN-4-ENE-3,20-DIONE AND RELATED USES](/abs-image/US/2024/07/25/US20240247026A1/abs.jpg.150x150.jpg)
2.发明公开公开(公告)号：US20240247026A1
公开(公告)日：2024-07-25
申请号：US18555707
申请日：2022-04-19
IPC分类号： C07J51/00 , A61K31/661
CPC分类号： C07J51/00 , A61K31/661
摘要： The present disclosure relates to a crystalline form of (((((E)-1-((8S,9S,10R, 13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethylidene)amino)oxy)methyl dihydrogen phosphate), and pharmaceutically acceptable salts thereof, which may be useful in methods of treatment of the human or animal body. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them and to their use in the treatment of disorders, such as managing inflammation (e.g., inflammation resulting from traumatic brain injury or stroke).
-
3.发明公开公开(公告)号：US20230190770A1
公开(公告)日：2023-06-22
申请号：US18107965
申请日：2023-02-09
IPC分类号： A61K31/58 , C07J1/00 , C07J5/00 , C07J7/00 , C07J21/00 , C07J41/00 , C07J9/00 , C07J13/00 , A61K31/56 , A61K31/565 , A61K31/566 , A61K31/573
CPC分类号： A61K31/58 , C07J1/0011 , C07J1/0018 , C07J1/0029 , C07J5/0015 , C07J7/002 , C07J21/00 , C07J41/0005 , C07J41/0094 , C07J9/005 , C07J13/007 , A61K31/56 , A61K31/565 , A61K31/566 , A61K31/573 , C07J21/006 , C07J21/008 , C07J51/00
摘要： The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
-
4.发明申请公开(公告)号：US20180318318A1
公开(公告)日：2018-11-08
申请号：US15775647
申请日：2016-11-12
发明人： Dong Wang , Fang Yuan , Zhenshan Jia , Xiaobei Wang
CPC分类号： A61K31/57 , A61K9/1075 , A61K47/10 , A61K47/34 , C07J41/0005 , C07J41/0016 , C07J51/00
摘要： Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for treating inflammatory and autoimmune diseases, including but not limited to lupus, are disclosed.
-
公开(公告)号：US20180305397A1
公开(公告)日：2018-10-25
申请号：US15966703
申请日：2018-04-30
发明人： André Steiner , Heidi Waenerlund Poulsen , Emilie Jolibois , Melissa Rewolinski , Ralf Gross , Emma Sharp , Fiona Dubas-Fisher , Alex Eberlin
IPC分类号： C07J9/00 , C07J51/00 , A61K31/575
CPC分类号： C07J9/005 , A61K9/2054 , A61K31/575 , C07B2200/13 , C07J51/00
摘要： The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
-
公开(公告)号：US20180264448A1
公开(公告)日：2018-09-20
申请号：US15763468
申请日：2016-09-30
申请人： THE REGENT OF THE UNIVERSITY OF MICHIGAN , THE FUNDACIO INSTITUTCATALA D'INVESTIGACIIO QUIMICA (ICIQ)
IPC分类号： B01J31/22 , C07F15/04 , C07B43/04 , C07B47/00 , C07B37/02 , C07C1/32 , C07C17/35 , C07C209/10 , C07D295/073 , C07F7/18 , C07J51/00
CPC分类号： B01J31/2291 , B01J31/2273 , B01J2231/323 , B01J2231/4227 , B01J2231/4283 , B01J2231/4288 , B01J2531/847 , B01J2540/10 , C07B37/02 , C07B37/04 , C07B43/04 , C07B47/00 , C07C1/321 , C07C17/35 , C07C209/10 , C07D295/073 , C07F7/188 , C07F15/04 , C07J51/00
摘要： Provided herein are nickel(O) catalysts that are stable when exposed to air and can be used to catalyze the formation of a C—C, C—O, or C—N bond.
-
公开(公告)号：US20180237471A1
公开(公告)日：2018-08-23
申请号：US15896400
申请日：2018-02-14
发明人： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
CPC分类号： C07J41/005 , C07J9/005 , C07J41/0055 , C07J43/003 , C07J51/00
摘要： The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10053485B2
公开(公告)日：2018-08-21
申请号：US15077099
申请日：2016-03-22
申请人： Evestra, Inc.
发明人： Hareesh Nair , Bindu Santhamma , Klaus Nickisch
IPC分类号： C07J1/00 , C07J11/00 , C07J31/00 , C07J41/00 , C07J43/00 , C07J21/00 , C07J51/00 , C07J71/00
CPC分类号： C07J1/0096 , C07J11/00 , C07J21/006 , C07J31/006 , C07J41/0083 , C07J43/003 , C07J51/00 , C07J71/001
摘要： Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
-
公开(公告)号：US09982008B2
公开(公告)日：2018-05-29
申请号：US14979005
申请日：2015-12-22
发明人： André Steiner , Heidi Waenerlund Poulsen , Emilie Jolibois , Melissa Rewolinski , Ralf Gross , Emma Sharp , Fiona Dubas-Fisher , Alex Eberlin
IPC分类号： A61K31/56 , C07J9/00 , A61K31/575 , C07J51/00 , A61K9/20
CPC分类号： C07J9/005 , A61K9/2054 , A61K31/575 , C07B2200/13 , C07J51/00
摘要： The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
-
公开(公告)号：US20180117065A1
公开(公告)日：2018-05-03
申请号：US15564799
申请日：2016-04-06
发明人： Mark PRUZANSKI , Luciano ADORINI
IPC分类号： A61K31/575 , A61K45/06 , A61P1/16 , A61P3/10 , A61P3/04
CPC分类号： A61K31/575 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61K38/26 , A61K45/06 , A61K47/542 , A61P1/16 , A61P3/04 , A61P3/10 , C07J9/005 , C07J51/00 , A61K2300/00
摘要： The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a FXR mediated disease or condition, such as NAFLD and NASH, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity.
-
-
-
-
-
-
-
-
-
搜索结果
727 条记录 (耗时 0.047 秒)
